Immune responses to liver-stage parasites: Implications for vaccine development

Chemical Immunology

Volumn 80, Issue , 2002, Pages 97-124

  Hollingdale, Michael R ^a   Krzych, Urszula ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANTIGEN DETECTION; ANTIGEN RECOGNITION; CELL PROTECTION; CELL ULTRASTRUCTURE; GENE SEQUENCE; HOST PARASITE INTERACTION; IMMUNE RESPONSE; IMMUNIZATION; LIFE CYCLE; LIVER PARENCHYMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPOROZOITE; VACCINE PRODUCTION;

EID: 0036093221     PISSN: 10150145     EISSN: None     Source Type: Journal    
DOI: 10.1159/000058841     Document Type: Review

References (154)

1. In vitro culture of the exoerythrocytic stage of Plasmodium berghei from sporozoites
2. An estimation of the number of sporozoites ejected by a feeding mosquito
3. Feeding behaviour and sporozoite ejection by infected Anopheles stephensi
4. Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes
5. Thrombospondin-related anonymous protein of Plasmodium falciparum binds specifically to sulfated glycoconjugates and to HepG2 hepatoma cells, suggesting a role for this molecule in sporozoite invasion of hepatocytes
6. Sporozoite invasion
7. Fine structure of the liver forms of the malaria parasite Plasmodium falciparum in human hepatocytes in vitro
8. Ultrastructure of in vitro cultured exoerythrocytic stage of Plasmodium berghei in a hepatoma cell line
9. Expression of Plasmodium berghei circumsporozoite protein on the surface of exoerythrocytic schizonts and merozoites
10. A malaria-heat-shock-like determinant expressed on the infected hepatocyte surface is a target of antibody-dependent cell-mediated cytotoxic mechanisms by non-parenchymal liver cells
11. Observations on early and late post-sporozoite tissue stages in primate malaria. IV. Pre-erythrocytic schizonts and/or hypnozoites of Chesson and North Korean strains of Plasmodium vivax in the chimpanzee
12. In vitro infectivity of irradiated P. berghei sporozoites to cultured hepatoma cells
13. Stage-specific ribosomal RNA expression switched during sporozoite invasion of hepatocytes
14. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites
15. A liver stage-specific antigen of Plasmodium falciparum characterized by gene cloning
16. Structure of Plasmodium falciparum liver stage antigen-1
17. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants
18. Non-CS pre-erythrocytic protective antigens
19. Exoerythrocytic merozoites of Plasmodium berghei in rat hepatic Kupffer cells
20. Localization of a 230 kDa parasitophorous vacuole membrane antigen of Plasmodium berghei exoerythrocytic schizonts (LSA-2) by immunoelectron and confocal laser scanning microscopy
21. Analysis of immune responses against T- and B-cell epitopes from Plasmodium falciparum liver-stage antigen 1 in rodent malaria models and malaria-exposed human subjects in India
22. Attacking the infected hepatocyte
23. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3
24. A novel Plasmodium falciparum sporozoite and liver stage antigen (SALSA) defines major B, T helper, and CTL epitopes
25. Cellular response against exoerythrocytic from of Plasmodium berghei in rats
26. Plasmodium yoelii: 17-kDa hepatic and erythrocytic stage protein is the target of an inhibitory monoclonal antibody
27. The gene for an exported antigen of the malaria parasite Plasmodium falciparum cloned and expressed in Escherichia coli
28. Glutamate-rich Plasmodium falciparum antigen (GLURP)
29. P berghei sporozoite immunization protects against P berghei sporozoite infection
30. A protective monoclonal antibody with dual specificity for Plasmodium falciparum and P. berghei circumsporozoite proteins
31. An antigen specific to the liver stage of rodent malaria recognized by a monoclonal antibody
32. Expression of heat shock proteins (members of the hsp70 family) in the hepatic stages of Plasmodium falciparum and P. berghei
33. Mature liver stages of cloned Plasmodium falciparum share epitopes with proteins from sporozoites and asexual blood stages
34. Immune effector mechanisms in malaria
35. The complexity of protective immunity against liver-stage malaria
36. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells: An in vitro assay of protective antibodies
37. Hybridoma produces antibodies directed against the sporozoite stage of malaria parasite
38. Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes
39. Gamma-interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites
40. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites
41. A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and P. berghei
42. Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon
43. Recombinant human gamma interferon inhibits simian malaria
44. IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism
45. Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: Involvement of interferon-γ and CD8+ T cells
46. Interleukin-12 induction of interferon gamma-dependent protection against malaria
47. Sterile protection of monkeys against malaria after administration of interleukin-12
48. Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria
49. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
50. Elimination of P. berghei liver stages is independent of Fas (CD95/Apo-1) or perforin-mediated cytotoxicity
51. Perforin- and Fas-mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice
52. Central role of endogenous gamma interferon in protective immunity against blood-stage Plasmodium chabaudi AS infection
53. Development of anti-malaria immunity in mice lacking IFN-gamma receptor
54. CD4+ cytotoxic T cell clone confers protection against murine malaria
55. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: Identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein
56. Gamma delta T cells contribute to immunity against the liver stages of mice in alpha beta T-cell-deficient mice
57. Gamma delta T cells are a component of early immunity against preerythrocytic malaria parasites
58. T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage antigens
59. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: Immunodominant T-cell domains map to the polymorphic regions of the molecule
60. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants
61. MHC class I-dependent presentation of exoerythrocytic antigens to CD8+ T lymphocytes is required for protective immunity against Plasmodium berghei
62. Pre-erythrocytic malaria vaccine: Mechanisms of protective immunity and human vaccine trials
63. Tolerance, danger and the extended family
64. Prometheus through the looking glass: Reflections on the hepatic immune system
65. Why does Plasmodium have a pre-erythrocytic cycle
66. Eosinophil-rich, granulomatous inflammatory response to Plasmodium berghei hepatic schizonts in non-immunized rats is age-related
67. Malaria and the liver: Tolerance and immunity to attenuated plasmodia sporozoites
68. Characterization of liver lymphomyloid cells in mice infected with Plasmodium yoelii sporozoites
69. Protective immunity against malaria: Cellular changes in the liver vary according to the method of immunization
70. The role of intrahepatic lymphocytes in mediating protective immunity induced by attenuated Plasmodium berghei sporozoites
71. Memory phenotype CD8 + T cells persist in livers of mice protected against malaria by immunization with attenuated Plasmodium berghei sporozoites
72. Strange brew: T cells in the liver
73. The liver as a site of T-cell apoptosis: Graveyard, or killing field?
74. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites
75. CD8+ T-cell protective immunity induced by immunization with Plasmodium berghei CS protein-derived synthetic peptides: Evidence that localization of peptide-specific CTLs is crucial for protection against malaria
76. The in vivo cytolytic activity of CD8+ T cell clones correlates with their levels of expression of adhesion molecules
77. NK1.1 + T cell receptor αβ+ cells: New clues to their origin, specificity and function
78. Mouse NK1.1 + T cells: A new family of T cells
79. Cytotoxic NK1.1 Ag + αβ T cells with intermediary TCR induced in the liver of mice by IL-12
80. IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model
81. A role for CD4+ NK1.1 + T lymphocytes as major histocompatibility complex class II independent helper cells in the generation of CD8+ effector function against intracellular infection
82. Liver NK1.1 + CD4+ αβ T cells activated by IL-12 as a major inhibition of experimental tumor metastasis
83. Immunity to intracellular bacteria
84. Detection of CD4 + CD45RO + T lymphocytes producing IL-4 in response to antigens on Plasmodium falciparum erythrocytes: An in vitro correlate of protective immunity induced with attenuated Plasmodium falciparum sporozoites
85. Liver CD4- CD8-NK1.1 + TCR alpha beta intermediate cells increase during experimental malaria infection and are able to exhibit inhibitory activity against the parasite liver stage in vitro
86. Predominance of one T-cell antigen receptor BV haplotype in African populations
87. Common west African HLA antigens are associated with protection from severe malaria
88. Molecular analysis of HLA-disease association: HLA-B53 and resistance to severe malaria
89. T cell immunity to peptide epitopes of liver-stage antigen I in an area of Papua New Guinea in which malaria is holoendemic
90. Influence of age and HLA type on IFNγ responses to a naturally occurring polymorphic epitope of Plasmodium falciparum liver stage antigen-1
91. Cytokine responses to Plasmodium falciparum liver-stage antigen 1 vary in rainy and dry seasons in highland Kenya
92. Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children
93. HLA-DQB1*0501-restricted Th1 type immune responses to Plasmodium falciparum liver stage antigen 1 protect against malaria anemia and reinfections
94. Interleukin-10 responses to liver-stage antigen 1 predict human resistance to Plasmodium falciparum
95. Parasite antigen-specific interleukin-10 and antibody responses predict accelerated parasite clearance in Plasmodium falciparum malaria
96. Factors influencing resistance to reinfection with Plasmodium falciparum
97. Interleukin 10-mediated immunosuppression by a variant CD4+ T cell epitope of Plasmodium falciparum
98. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes
99. Human IL-10 is a chemo-attractant for CD8+ T lymphocytes and an inhibitor of IL-8-induced CD4+ T lymphocyte migration
100. Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3
101. Plasmodium falciparum sporozoite invasion is inhibited by naturally acquired or experimentally induced polyclonal antibodies to the STARP antigen
102. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal
103. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro
104. Cloning of a Plasmodium falciparum gene related to the human 60-kDa heat shock protein
105. Immunogenetics. Defence by diversity
106. HIV and HLA Confusion or complexity?
107. Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria
108. Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles
109. HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles
110. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism
111. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules
112. Peptide binding function and the paradox of HLA disease associations
113. HLA and HIV-1 Heterozygote advantage and B*35-Cw*04 disadvantage
114. Heterozygote advantage for HLA class-II type in hepatitis B virus infection
115. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria
116. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in the Gambia
117. CpG motifs in bacterial DNA trigger direct B-cell activation
118. CpG DNA in cancer immunotherapy
119. Immunology of DNA vaccines: CpG motifs and antigen presentation
120. Gee whiz: CpG DNA allergy therapy!
121. Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins
122. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major
123. CpG DNA augments the immunogenicity of plasmid DNA vaccines
124. Contribution of CpG motifs to the immunogenicity of DNA vaccines
125. DNA vaccines: Immunology, application, and optimization
126. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys
127. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development
128. Co-immunization with DNA vaccines expressing granulocyte-macrophage colony-stimulating factor and mycobacterial secreted proteins enhances T-cell immunity, but not protective efficacy against Mycobacterium tuberculosis
129. Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes
130. Prevention of neonatal tolerance by a plasmid encoding granulocyte-macrophage colony stimulating factor
131. Granulocyte-macrophage colony-stimulating factor production by T lymphocytes in Plasmodium berghei-infected mice
132. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine
133. Improving protective immunity induced by DNA-based immunization: Priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus
134. Lipopeptide derivatives of bacterial lipoprotein constitute potent immune adjuvants combined with or covalently coupled to antigen or hapten
135. Synthetic lipopeptides as novel adjuvants
136. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells
137. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria
138. Expression and immunogenicity of a liver stage malaria epitope presented as a foreign peptide on the surface of RNA-free MS2 bacteriophage capsids
139. Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL
140. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees
141. Immunogenicity of four Plasmodium falciparum preerythrocytic antigens in Aotus lemurinus monkeys
142. High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules
143. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide
144. Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli
145. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD9+ T-cell-mediated protective immunity against malaria
146. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine
147. Enhancement of MHC class I restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime
148. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: Enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models
149. Direct immunization of malaria DNA vaccine into the liver by gene gun protects against lethal challenge of Plasmodium berghei sporozoite
150. Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles
151. Ty virus-like particles, DNA vaccines and modified vaccinia virus Ankara: Comparisons and combinations
152. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use
153. A protein particle vaccine containing multiple malaria epitopes
154. Immunogenicity of Ty-VLP bearing a CD8+ T cell epitope of the CS protein of P. yoelii enhanced memory response by boosting with recombinant vaccinia virus